Mark Avagliano, Chief Business Officer at G1 Therapeutics, Inc. (GTHX), sold 2,638 shares at $2.51 ($7K) on 2024-07-05, disclosed to the SEC on 2024-07-08.
Open-market sale of $7k GTHX by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| GTHX | SELL | 2022-01-05 | $15K | — | Filing → |